Current filters:

Eprosartan Mesylate

1 to 9 of 39 results

Kos enters cardiovascular R&D alliance with Biovail


US firm Kos Pharmaceuticals has entered into a strategic commercialization and R&D alliance with Canada's…

Cardizem LADiltiazemDiltiazem HclEnalaprilEprosartan MesylateEprosartan Mesylate Hydrochlorothiazide TableSolvayTevetenTeveten HCTTiazacVasotec

Biovail revises full-year outlook on robust sales


Canadian drugmaker Biovail Corp has updated its revenue guidance for2004, narrowing its previous sales…

AcyclovirBupropion HclBupropion Hydrochloride Extended-ReleaseCardizem LADiltiazemEprosartan MesylateTevetenWellbutrinWellbutrin XLZoviraxZyban

FDA clears Biovail's Cardizem LA for the treatment of angina


The US Food and Drug Administration has approved the use of Canada-based Biovail's hypertension drug,…

Cardizem LADiltiazemEprosartan MesylateEprosartan Mesylate Hydrochlorothiazide TableTevetenTeveten HCT

Novel promotion deal for Altana and Solvay


Germany's Altana Pharma and Belgium-based Solvay have entered a novel co-promotion arrangement in the…

ALTANA PharmaEprosartan MesylateSolvayTeveten

Sales and profits down at Belgium's Solvay


Belgium's Solvay has reported a 6% drop in profits to 3.79 billion euros ($4.36 billion) for the first…

Eprosartan MesylateSolvayTeveten

Biovail gets US OK for Teveten HCT


Canada's Biovail Corp has been granted US approval to market Teveten HCT(eprosartan mesylate and hydrochlorothiazide)…

Eprosartan MesylateEprosartan Mesylate Hydrochlorothiazide TableSolvayTevetenTeveten HCT

Solvay pharma earnings grow 13%


Belgium's Solvay Group reported pharmaceutical sales of 1.86 billioneuros ($2 billion), a rise of 5%…

Eprosartan MesylateSolvayTeveten

1 to 9 of 39 results

Back to top